Research

A new study from researchers at Fox Chase Cancer Center and collaborators across multiple institutions has identified a hidden subset of lung cancers that behave more like aggressive neuroendocrine tumors than traditional non-small cell lung cancer (NSCLC).

In a new Fox Chase Cancer Center study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Anthony Olszanski, MD, RPh, and colleagues evaluated gamitrinib, an experimental therapy designed to exploit this vulnerability. Gamitrinib is a first-in-class therapy engineered to act inside cancer cell mitochondria, disrupting key survival functions tumors use to grow and resist treatment.

A nurse-driven quality improvement initiative at Fox Chase Cancer Center has dramatically reduced same-day chemotherapy infusion cancellations, improved patient education and experience, and generated significant cost savings.

Physicians from the Fox Chase-Temple Urologic Institute will present new research and clinical insights at the 2026 American Urological Association Annual Meeting, where they will highlight advances in kidney cancer treatment, penile prosthesis surgery, and the management of prolonged priapism.

At the American Association for Cancer Research (AACR) Annual Meeting 2026, Fox Chase Cancer Center did not just share research findings. Its scientists helped shape the questions guiding where cancer research is headed next; questions about how cancer begins, how it changes over time, and how it might be stopped earlier than ever before.

Fox Chase researchers developed a new tool that helps clinicians understand whether the tissue surrounding a pancreatic tumor is helping fight the cancer or allowing it to grow. In the lab, the team found that a specialized form of radiation treatment can change the tumor environment to potentially work against the cancer.

A Fox Chase Cancer Center study using young, middle‑aged and geriatric mice suggests melanoma incidence and mortality are strongly age‑dependent and that age‑related immune changes can promote aggressive melanoma spread, particularly in middle age.

Researchers at Fox Chase Cancer Center have demonstrated that extending postoperative blood clot prevention medication for patients undergoing DIEP flap breast reconstruction significantly reduces the risk of venous thromboembolism (VTE), a potentially life-threatening complication.